Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease

Haemostasis

Volumn 30, Issue SUPPL. 3, 2000, Pages 27-43

  Berkowitz, Scott D ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Coronary artery disease; Glycoprotein IIb IIIa; Percutaneous coronary revascularization; Platelet aggregation inhibitors; Platelet receptor antagonists

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LAMIFIBAN; TIROFIBAN;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

EID: 0034486796     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054195     Document Type: Conference Paper

References (63)

1. The pathogenesis of coronary artery disease and the acute coronary syndromes (1)
2. The pathogenesis of coronary artery disease and the acute coronary syndromes (2)
3. Angioscopic observation of the coronary luminal changes induced by percutaneous transluminal coronary angioplasty
4. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: Results of the Veterans Administration Cooperative Study
5. Aspirin, heparin, or both to treat acute unstable angina
6. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease
7. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients
8. The platelet membrane glycoprotein IIb/IIIa complex
9. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine
10. Blockade of platelet GPIIb/IIIa receptors as an anti-thrombotic strategy
11. Glycoprotein IIb/IIIa integrin blockade
12. Platelet glycoprotein IIb/IIIa receptor antagonists: Current concepts and future directions
13. Anti-platelet therapy in interventional cardiology: II. Glycoprotein IIb/IIIa inhibitors
14. Coronary intervention and glycoprotein IIb/IIIa integrin blockade
15. Glycoprotein IIb/IIIa inhibitors in unstable angina and non-ST segment elevation myocardial infarction
16. Glycoprotein IIb/IIIa inhibitors in acute ST segment elevation myocardial infarction
17. Platelet GPIIb-IIIa blockers
18. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
19. Integrins: A family of cell surface receptors
20. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis
21. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis
22. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets and binds to glycoproteins IIb and/or IIIa
23. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty
24. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade
25. Platelet membrane defects in Glanzmann's thrombasthenia: Evidence for decreased amounts of two major glycoproteins
26. Novel antiplatelet agents: The glycoprotein IIb/IIIa inhibitors
27. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention
28. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty
29. Oral platelet glycoprotein IIb/IIIa inhibitors
30. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II
31. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
32. Platelet glycoprotein IIb/IIIa receptor blockade, low-dose heparin during percutaneous coronary revascularization
33. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
34. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
35. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina. The CAPTURE, study
36. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction
37. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
38. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting
39. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis
40. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months
41. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta 3 blockade with percutaneous coronary intervention
42. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: One-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade
43. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors
44. Bleeding complications with platelet glycoprotein IIb/IIIa receptor antagonists
45. Incidence of intracranial hemorrhage in trials of glycoprotein IIb/IIIa receptor inhibitor drugs
46. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
47. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
48. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
49. International, randomized controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina
50. Maintenance of clinical benefit at 6 months in patients treated with platelet glycoprotein IIb/IIIa inhibitor eptifibatide versus placebo during an acute ischemic coronary event
51. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
52. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery
53. Routine platelet transfusion in patients undergoing emergency coronary bypass surgery after receiving abciximab
54. Is bleeding risk increased in patients undergoing urgent bypass surgery following abciximab
55. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization
56. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade
57. Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors
58. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy
59. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial experience
60. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa
61. Efficacy of abciximab readministration in coronary intervention
62. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial
63. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes A randomised trial